News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Acucela Inc. Appoints Former Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. Executive, Jaisim Shah, to the Company’s Board of Directors
August 3, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced that it has appointed Mr. Jaisim Shah to the Company’s Board of Directors.
Twitter
LinkedIn
Facebook
Email
Print
People
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Layoff Tracker
Immutep, Molecular cut workforces
October 30, 2026
·
113 min read
·
BioSpace Editorial Staff
Earnings
AstraZeneca employs $1.5B cost savings to reinvest back into growth
October 30, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
October 30, 2026
·
4 min read
·
Heather McKenzie
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
October 30, 2026
·
2 min read
·
Nick Paul Taylor